Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study

doi:doi:10.1038/sj.bjc.6601071

British Journal of Cancer (2003) 89, 966–967. doi:10.1038/sj.bjc.6601071 www.bjcancer.com
Published online 9 September 2003

Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study

O M McNally¹, E Delaney¹, R D Petty², M E Cruickshank¹, A W Hutcheon² and D E Parkin¹

¹Department of Gynaecology/Oncology, Ward 43, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB15 2ZN, Scotland
²Department of Clinical Oncology, Ward 43, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB15 2ZN, Scotland

Correspondence: Miss OM McNally, E-mail: omcnally@doctors.org.uk

Received 30 October 2002; Revised 4 March 2003; Accepted 27 March 2003.

Top

Abstract

NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.